CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Carvajal from Memorial Sloan-Kettering Cancer Center in New York presented results from a Phase II study with 98 patients randomised to receive an old drug, temozolomide, or selumetinib which inhibits the MEK pathway affected by GNAQ and GNA II gene mutations commonly found in this rare tumour. He discussed findings with Peter Goodwin.
You may also like...
Ultrahypofractionated Radiation Just As Effective for Prostate Cancer 16 May, 2018 Time from nephrectomy to metastasis confirmed as prognostic in patients with renal cell carcinoma treated with targeted therapies 13 Feb, 2014 Gene expression and molecular pathways guide head and neck cancer therapies 24 Apr, 2013 Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide 14 Dec, 2007
- Previous story Audio Journal of Oncology with Oncology Times, June 2013
- Next story Patients with oropharyngeal cancer: no HPV risk to spouses, partners
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014